Acer Therapeutics Inc.

0.8044-0.0259-3.12%Vol 125.79K1Y Perf -38.95%
Sep 22nd, 2023 16:00 DELAYED
BID0.8010 ASK0.8200
Open0.8111 Previous Close0.8303
Pre-Market- After-Market0.80
 - -  0.00 -0.55%
Target Price
11.00 
Analyst Rating
Moderate Buy 2.33
Potential %
1.27K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
     38.80
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
6.31 
Earnings Rating
Strong Buy
Market Cap19.68M 
Earnings Date
13th Nov 2023
Alpha-0.02 Standard Deviation0.25
Beta0.44 

Today's Price Range

0.80340.8390

52W Range

0.55154.56

5 Year PE Ratio Range

-4.00-1.90

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-6.92%
1 Month
23.72%
3 Months
-8.59%
6 Months
4.20%
1 Year
-38.95%
3 Years
-67.30%
5 Years
-97.40%
10 Years
-99.46%

TickerPriceChg.Chg.%
ACER0.8044-0.0259-3.12
AAPL174.790.86000.49
GOOG131.25-0.1100-0.08
MSFT317.01-2.5200-0.79
XOM114.940.18000.16
WFC41.23-1.0900-2.58
JNJ160.50-1.1600-0.72
FB196.640.99000.51
GE111.25-1.7400-1.54
JPM145.73-1.4100-0.96
Financial StrengthValueIndustryS&P 500US Markets
0.30
0.40
0.01
0.04
-4 429.70
Leverage Ratio -2.20
ProfitabilityValueIndustryS&P 500US Markets
-
-6 603.00
-6 582.90
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q02 2023-0.26-0.2311.54
Q01 2023-0.291.08472.41
Q04 2022-0.35-0.328.57
Q03 2022-0.76-0.3159.21
Q02 2022-0.58-0.4817.24
Q01 2022-0.18-0.49-172.22
Q04 2021-0.08-0.31-287.50
Q03 2021-0.28-0.2317.86
Earnings Per EndEstimateRevision %Trend
9/2023 QR-0.1335.00Positive
12/2023 QR-0.0820.00Positive
12/2023 FY-0.3238.46Positive
12/2024 FY0.120.00-
Next Report Date13th Nov 2023
Estimated EPS Next Report-0.13
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume125.79K
Shares Outstanding24.46K
Shares Float19.96M
Trades Count552
Dollar Volume102.82K
Avg. Volume3.03M
Avg. Weekly Volume221.55K
Avg. Monthly Volume6.55M
Avg. Quarterly Volume2.32M

Acer Therapeutics Inc. (NASDAQ: ACER) stock closed at 0.8044 per share at the end of the most recent trading day (a -3.12% change compared to the prior day closing price) with a volume of 125.79K shares and market capitalization of 19.68M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 18 people. Acer Therapeutics Inc. CEO is Chris Schelling.

The one-year performance of Acer Therapeutics Inc. stock is -38.95%, while year-to-date (YTD) performance is -67.95%. ACER stock has a five-year performance of -97.4%. Its 52-week range is between 0.5515 and 4.56, which gives ACER stock a 52-week price range ratio of 6.31%

Acer Therapeutics Inc. currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 16.46, a price-to-sale (PS) ratio of 201.62, a price to cashflow ratio of 31.40, a PEG ratio of -, a ROA of -99.18%, a ROC of -147.90% and a ROE of 410.14%. The company’s profit margin is -%, its EBITDA margin is -6 582.90%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Acer Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.13 for the next earnings report. Acer Therapeutics Inc.’s next earnings report date is 13th Nov 2023.

The consensus rating of Wall Street analysts for Acer Therapeutics Inc. is Moderate Buy (2.33), with a target price of $11, which is +1 267.48% compared to the current price. The earnings rating for Acer Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Acer Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Acer Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.98, ATR14 : 0.10, CCI20 : -22.47, Chaikin Money Flow : -0.12, MACD : 0.01, Money Flow Index : 22.58, ROC : -7.47, RSI : 47.81, STOCH (14,3) : 1.63, STOCH RSI : 0.00, UO : 46.88, Williams %R : -98.37), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Acer Therapeutics Inc. in the last 12-months were: Chris Schelling (Buy at a value of $1 000 000), Stephen Aselage (Buy at a value of $500 000)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (33.33 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (66.67 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.33
Strong Buy
1.00
Strong Buy
1.00

Acer Therapeutics Inc.

Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medical need. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease.

CEO: Chris Schelling

Telephone: +1 844 902-6100

Address: 300 Washington Street, Newton 02458, MA, US

Number of employees: 18

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

59%41%

Bearish Bullish

59%41%

 

TipRanks News for ACER

Thu, 31 Aug 2023 11:37 GMT Zevra Therapeutics to acquire Acer Therapeutics in potential $91M transaction

- TipRanks. All rights reserved.

News

Stocktwits